News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News 📰

Dengue Vaccine Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: January 2024 || SKU: PH1560
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of tables & Figures
Get Free Sample

See how US Tariffs impact Dengue Vaccine Market

Don’t get caught off

Global Dengue Vaccine Market is segmented By Product Type (CYD-TDV), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

 

Dengue Vaccine Market Size

The Global Dengue Vaccine Market size was valued at USD million in 2023 and is estimated to reach USD million by 2031, growing at a CAGR of 10.4% during the forecast period (2024-2031). Dengue is a mosquito-borne infectious ailment that influences people and animals and is a result of the dengue virus belonging to the Flaviviridae’s circle of relatives and genus Flavivirus.

Dengue is likewise recognized as breakbone fever or “dandy fever. It is a usually transmitted ailment from human to human via the chew of an inflamed Aedes aegypti mosquito. Common signs of dengue encompass headache, excessive fever, fatigue, muscle pain, diarrhea, anemia, vomiting and pores and skin rashes. Dengue vaccine is a vaccine used to prevent dengue fever in humans. Several vaccines are under clinical trial that show promising effects, including TVD, TV003, TV005, TVDV and TV.

Source: DataM Intelligence Analysis (2021

Dengue Vaccine Market Scope

Metrics

Details

Market CAGR

10.4%

Segments Covered

By Product Type, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

 

For More Insights Request Free Sample

 

Dengue Vaccine Market Dynamics

The increasing prevalence of dengue cases, increasing clinical trials by the key market players and rising vaccine development funds are driving the market in the forecast period. 

Increasing Collaborations by the Research Institutes for the Clinical Trials of the Dengue Vaccine is Expected to Drive Market Growth.

With the upward push in dengue instances throughout the country, the Indian Council of Medical Research (ICMR) has launched an initiative to facilitate the improvement of a dengue vaccine. Vaccine producers and pharma corporations who've advanced or have the license of tetravalent dengue vaccine candidate and feature finished its segment I and segment II medical trials can collaborate with ICMR for carrying out segment III trials and the next improvement of the vaccine. 

In addition, the apex biomedical studies institute will provide institutional infrastructure for project studies and development (R&D) sports and phase-III scientific trials for assessment of efficacy alongside protection and immunogenicity of tetravalent dengue vaccine candidate evolved via way of means of Indian producers or having the license for the same.

For instance, on March 4, 2022, it invited expressions of interest from Indian manufacturers who have developed potential tetravalent vaccine candidates or have a non-exclusive license of the tetravalent vaccine candidates and intend to conduct field studies as phase-III clinical trials. Therefore, the collaboration of manufacturers with the ICMR for phase-III clinical trials of the dengue vaccine is expected to drive the market in the forecast period.

Challenges During Dengue Vaccine Development are Expected to Hamper the Market Growth.

Several challenging situations have hindered the improvement of the dengue vaccine. One of those demanding situations is the structural similarities among DENV and different individuals of the Flaviviridae own circle of relative viruses, together with the Zika virus (ZIKV), Yellow fever virus (YFV), Japanese encephalitis virus (JEV) and West Nile virus (WNV). 

The envelope protein (E) is each structurally conserved amongst flaviviruses and the maximum uncovered protein the immune gadget generates antibodies towards to neutralize the virus. Furthermore, lack of awareness among people about the dengue vaccine and rigid competition among existing players to develop a new vaccine are the factors to hamper the market in the forecast period.

COVID-19 Impact on Dengue Vaccine Market 

The coronavirus pandemic has moderately impacted the dengue vaccine market. Pre-exposure to DENV may provide some degree of cross-protection to SARS-CoV-2 infection, rendering it less severe in the regions where DENV infections occur rampantly and regularly. Countries, where BCG vaccination is recommended (in early childhood) have also been observed to be less affected by COVID-19. 

This appears true for highly DENV endemic (& BCG vaccine compliant) countries like India and Argentina but is in question for low/sporadic DENV-reporting (yet BCG vaccination compliant) countries like Iran and China, where COVID-19 had a serious impact so far. The high levels of infections and mortality in Brazil (another BCG vaccination-compliant country) have also put the theory that BCG vaccination could be protective against COVID-19. Therefore, the demand for the dengue vaccine increased.

In contrast, the pandemic has diverted resources and finances. And it has kept dengue vaccine development out of the international spotlight. The resurgence of dengue fever is a real threat during the COVID-19 pandemic. The high burden of dengue-related hospitalizations will further overwhelm an already overwhelmed healthcare system. 

Therefore, the COVID-19 pandemic has further impetus the development, approval and introduction of dengue vaccines for wider use. Thus, from the above factors, the market got affected and it is expected to improve in the forecast period.

Dengue Vaccine Market Segment Analysis

CYD-TDV Vaccine Segment is Expected to Hold the Largest Market Share in the Dengue Vaccine Market   

The CYD-TDV vaccine segment accounted for the largest market share in 2021. CYD-TDV is a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone developed by Sanofi Pasteur. The schedule evaluated in Phase III clinical trials includes three doses of vaccine (at 0, 6 and 12 months). The CYD-TDV vaccine shows benefits for efficacy for virologically confirmed dengue (VCD), efficacy for severe VCD and efficacy for hospitalization for VCD.

Additionally, a dengue preventive vaccine (CYD-TDV, Dengvaxia) has been licensed in 20 countries and is available for people aged 9 to 45. The World Health Organization recommends that only people with a confirmed dengue infection be vaccinated. Furthermore, in May 2019, Dengvaxia was acquired by the United States. 

The U.S. Food and Drug Administration (FDA) uses it for children ages 9 to 16 who live in dengue-endemic areas with laboratory-confirmed dengue virus infection. Therefore, the demand for the CYD-TDV vaccine is increasing. Thus, from the above factors, the market segment accounts for the largest market share during the forecast period.

 Source: DataM Intelligence Analysis (2021)

Global Dengue Vaccine Market Geographical Share

South America Region Holds the Largest Market Share in the Global Dengue Vaccine Market.  

South America region accounted for the largest market share in 2021. The increasing prevalence of dengue cases, the high adoption of dengue vaccines in the region, rising mass vaccination and increasing clinical trials by the market players are the factors driving market growth in the forecast period. 

For instance, the Brazilian Ministry of Health has reported the continuing spread of dengue fever in all five regions. Between 1 January and 31 May 2022, 1,104,742 cases of dengue, including 504 deaths, were reported, which represents an increase of 198% in cases compared to the same period in 2021. Therefore, there is an increase in the demand for the dengue vaccine in the region.

Furthermore, the Brazilian state of Paraná conducted a mass vaccination campaign against dengue with the tetravalent attenuated vaccine CYD-TDV. The campaign targeted thirty endemic municipalities. Thus, from the above factors, the South American region accounted for the largest market share in the forecast period.

Source: DataM Intelligence Analysis (2021)

Dengue Vaccine Market Companies

Major key players in the dengue vaccine market are Sanofi, Panacea Biotec, Biological, E. Limited, GlaxoSmithKline plc, Merck & Co., Takeda Pharmaceutical Company Ltd, Vabiotec, Panacea Biotec and Medigen Biologics.

On December 9, 2022, the European Commission (EC) granted marketing authorization for Takeda’s Qdenga [Dengue Tetravalent Vaccine (Live, Attenuated)] (TAK-003) to prevent dengue in people aged four years and above.

Takeda Pharmaceuticals:

Overview:

Takeda Pharmaceuticals is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing people better health and a brighter future worldwide. The company discovers and develops innovative biological medicines, making them accessible to patients worldwide. Takeda Pharmaceuticals R&D efforts are focused on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). The company also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Product Portfolio:

QDENGA [Dengue Tetravalent Vaccine (Live, Attenuated)]: QDENGA (TAK-003) is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four dengue virus serotypes and is designed to protect against any of these serotypes.

 

The Global Dengue Vaccine Market Report Would Provide an Access to an Approx. 45+ Market Data Tables, 40+ Figures and 180 Pages.

Buy this report
Single User
$4350$3480
Multiple User
$4850$3880
Enterprise User
$7850$6280
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
Chat on WhatsApp
FAQ’s

  • Dengue Vaccine Market is expected to grow at a CAGR of 10.4% during the forecast period 2024-2031.

  • key players are Sanofi, Panacea Biotec, Biological, E. Limited, GlaxoSmithKline plc, Merck & Co., Takeda Pharmaceutical Company Ltd, Vabiotec, Panacea Biotec and Medigen Biologics.
Related Reports
pharmaceuticals iconpharmaceuticals

Meningitis Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 12

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Live Attenuated Vaccines Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 November 01

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Endometrial Cancer Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 December 20

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Osteotomy Plates Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 16

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Empty Capsules Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 September 12

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Over the Counter Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 16

Starting from

$4350

WhatsApp